There is no single life expectancy figure for Smith-Lemli-Opitz syndrome (SLOS) because the condition spans an enormous range of severity. Some infants with the most severe forms die within days or weeks of birth, while many people with milder presentations survive well into adulthood. The key factor shaping any individual’s outlook is how profoundly the underlying cholesterol deficiency disrupts organ development before and after birth, and research has found that baseline blood cholesterol levels explain a substantial share of that variation.
Why a Single Number Does Not Exist
SLOS is caused by a defect in the final step of the body’s cholesterol-making pathway. Cholesterol is not just a dietary concern; it is a building block for cell membranes, hormones, and the signals that guide fetal development. When the enzyme responsible for producing cholesterol does not work properly, every organ system can be affected to varying degrees. That variability is the reason you will not find a tidy median survival statistic the way you might for some other genetic conditions.
At the mild end, a person might have little more than fused second and third toes, subtle facial features, low muscle tone, and mild learning differences. At the severe end, infants can present with major heart defects, brain malformations, cleft palate, ambiguous genitalia, and failure of multiple organ systems at once.1Genetics in Medicine. Smith-Lemli-Opitz syndrome: a review of major research advances This is not a two-category situation; severity falls along a continuous spectrum, and where a person lands on that spectrum largely dictates their prognosis.
What Determines Whether Someone Survives Infancy
The most dangerous period is the first year of life. Infants born with severe cardiac malformations, major brain abnormalities, or profound cholestasis (a blockage of bile flow from the liver) face the highest mortality risk. One study examining liver involvement in cholesterol biosynthesis disorders found that cholestasis in SLOS was specifically associated with early death.2PubMed. Characterization of liver involvement in defects of cholesterol biosynthesis: long-term follow-up and review Hepatic fibrosis was also present, compounding the strain on a newborn’s body.
Blood cholesterol concentration at birth is one of the strongest predictors of how severe the disease will be. Research has found a negative correlation between clinical severity and serum cholesterol, with the very lowest levels (below about 7 mg/dL) tied to the highest mortality. An analysis of 32 patients estimated that roughly a third to two-fifths of the variation in a patient’s severity score could be attributed to plasma cholesterol levels alone, though other factors clearly play a role as well.3Genetics in Medicine. Smith-Lemli-Opitz syndrome: an updated review of clinical presentation, diagnosis, and management In practical terms, an infant whose body can still manufacture some cholesterol tends to have a milder course than one whose enzyme function is nearly absent.
Survival Into Adulthood
A common misconception is that SLOS is uniformly fatal in childhood. It is not. A study assessing postnatal mortality in SLOS found that although premature death does occur, many individuals with the syndrome survive into adulthood.4PubMed Central. Assessing Postnatal Mortality in Smith-Lemli-Opitz Syndrome Adults with SLOS exist across a range of functioning: some live semi-independently with support, while others require full-time care. The adults who do well tend to be those whose structural birth defects were absent or surgically correctable, whose cholesterol levels responded to dietary supplementation, and whose behavioral and cognitive challenges were addressed early.
That said, surviving into adulthood does not mean the condition becomes benign. Ongoing medical monitoring is typically needed for feeding difficulties, growth problems, hormonal imbalances, photosensitivity, and behavioral concerns. Life expectancy in the milder cases has not been formally quantified in large studies, partly because SLOS is rare and partly because the condition was only biochemically characterized in the 1990s, so the first generation of diagnosed adults is still relatively young.
Brain Differences and Their Role in Long-Term Outcomes
Cholesterol is critical for normal brain development, so it is not surprising that neurological findings are nearly universal in SLOS. An MRI study of 55 patients found abnormalities in 96% of them. The most common was an abnormality of the septum pellucidum, a thin membrane between the brain’s fluid-filled ventricles, seen in about three-quarters of patients. Abnormalities of the corpus callosum, the thick band of fibers connecting the two brain hemispheres, appeared in roughly 69%. Other findings included cerebral and cerebellar atrophy, white matter lesions, and cyst-like malformations.5PubMed Central. Brain magnetic resonance imaging findings in Smith-Lemli-Opitz syndrome
These structural differences do not all carry the same weight. Some, like minor thinning of the corpus callosum, may contribute to learning difficulties without threatening survival. Others, such as a Dandy-Walker malformation or severe cerebellar underdevelopment, can cause life-threatening complications including hydrocephalus. For families trying to understand a child’s prognosis, the specific pattern of brain findings on imaging often gives more useful information than the SLOS diagnosis alone.
Behavioral and Developmental Challenges
Intellectual disability ranges from absent or mild in the least-affected individuals to severe in those with major structural brain involvement. A study of children with SLOS aged 4 to nearly 18 found that higher clinical severity scores correlated with increased scores on measures of autism and intellectual disability.3Genetics in Medicine. Smith-Lemli-Opitz syndrome: an updated review of clinical presentation, diagnosis, and management
Beyond cognition, there is a recognizable behavioral pattern in SLOS. Systematic evaluations have shown that at least half of patients display aggressive or self-injurious behavior. The behavioral profile often includes persistent irritability, hyperactivity, hand flapping or flicking, and features that overlap with autism spectrum disorder.6PubMed Central. Challenging Behavior in Smith-Lemli-Opitz Syndrome: Initial Test of Biobehavioral Influences These behaviors are not merely inconvenient; they can affect whether a person tolerates medical procedures, feeds adequately, or can safely live in less restrictive settings. Managing them effectively is an important part of improving quality of life and, indirectly, long-term outcomes.
Treatment Approaches and Their Limits
There is no cure for SLOS, and the structural damage that occurs during fetal development cannot be reversed after birth. Treatment instead focuses on two goals: raising cholesterol levels in the body and reducing the toxic byproducts (dehydrocholesterol compounds, or DHC) that accumulate when the faulty enzyme cannot finish making cholesterol.
The most straightforward intervention is dietary cholesterol supplementation, usually through egg yolk or pharmaceutical-grade cholesterol added to a child’s food. This can raise blood cholesterol levels, and clinical experience suggests it helps with growth and behavior in some patients, though the evidence base is largely observational rather than from large controlled trials.7PubMed Central. Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders Dietary cholesterol does not cross the blood-brain barrier efficiently in postnatal life, which limits its ability to address the neurological aspects of the disease.
Statins, which in most people are used to lower cholesterol, have been investigated for a different reason in SLOS: they can reduce levels of the toxic DHC precursors. A placebo-controlled trial of simvastatin in 18 patients showed that the drug decreased DHC levels and the DHC-to-total-sterol ratio in nearly every participant.8PubMed Central. A Placebo-Controlled Trial of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome An earlier, smaller study confirmed that simvastatin worked through a different mechanism than cholesterol supplementation alone: while dietary cholesterol raised the cholesterol side of the ratio, adding simvastatin pushed down the DHC side.9PubMed. Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS) The hope is that lowering these toxic sterols might reduce oxidative damage to tissues, particularly the skin and possibly the brain. Whether this translates into longer survival or better cognitive outcomes remains an open question; the evidence so far mostly shows biochemical improvement rather than proven clinical benefit over years.10PubMed Central. Statins for Smith-Lemli-Opitz syndrome
Beyond these two pharmacological strategies, managing SLOS involves the same supportive care used for many complex developmental conditions: surgical repair of heart defects or cleft palate, tube feeding when oral intake is inadequate, physical and occupational therapy, behavioral interventions, and careful monitoring of liver and kidney function.
Prenatal Detection and Its Effect on Reported Statistics
One complication when interpreting SLOS survival data is that the most severe cases are often detected before birth and may never appear in postnatal statistics. Low maternal unconjugated estriol on routine prenatal screening can flag a pregnancy at risk, and ultrasound may reveal the major structural defects associated with severe SLOS. In one screening study, five of six SLOS pregnancies were screen-positive, all had sonographic findings, and all six were terminated.11PubMed. Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome In another report, two identified cases of SLOS did not survive the neonatal period; one pregnancy was terminated for severe oligohydramnios and the other infant died within 48 hours of birth.12PubMed. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other fetal conditions
This creates a statistical phenomenon sometimes called ascertainment bias. The most lethal cases are increasingly removed from postnatal cohorts through prenatal detection and elective termination, or they result in stillbirth. The children who are born alive and enter clinical follow-up skew toward the milder end of the spectrum. That means published survival rates among liveborn SLOS patients may look more optimistic than the condition’s natural history would otherwise suggest. Families receiving a prenatal diagnosis of severe SLOS should understand that the outlook described in postnatal studies may not reflect their specific situation.
How Common SLOS Is and Who Carries It
SLOS is rare overall but unevenly distributed across populations. A large genetic study of carrier frequencies across ethnic groups found that the highest rate was among Ashkenazi Jews, at about 1 in 42 people carrying one copy of a disease-causing variant. All populations of European origin had carrier frequencies above 1%. The lowest rates were in South Asian populations, at about 1 in 1,477, and carrier status was generally uncommon across Asian groups.13PubMed Central. Smith–Lemli–Opitz syndrome carrier frequency and estimates of in utero mortality rates
Despite the relatively high carrier frequency in some populations, the birth prevalence is lower than you would predict from carrier rates alone. Researchers suspect this gap reflects significant in-utero loss: many severely affected embryos likely miscarry before reaching a gestational age at which they would be diagnosed. The same study explored estimates of in-utero mortality and found the discrepancy between expected and observed birth prevalence to be substantial, reinforcing the idea that the most severe genotypes often do not result in a live birth at all.
Photosensitivity and Skin Damage
One aspect of SLOS that many families do not anticipate is an unusual sensitivity to ultraviolet light. The toxic dehydrocholesterol compounds that build up in the skin absorb UV radiation and generate reactive oxygen species, essentially creating a sunburn-like reaction more easily than normal skin would experience. This is more than a cosmetic nuisance. Chronic oxidative damage to the skin can be painful, limit outdoor activity, and contribute to inflammation that affects wellbeing. Some researchers believe the biochemical improvements from statin therapy may partly help by reducing the concentration of these photosensitizing sterols in the skin, though direct evidence of reduced sunburn susceptibility from treatment is still limited.
For day-to-day management, aggressive sun protection with clothing, hats, and broad-spectrum sunscreen is standard advice. Families sometimes report that dietary cholesterol supplementation also seems to reduce photosensitivity, though the mechanism for that is less clear and formal evidence is thin.
Living With SLOS as an Adult
As the first wave of diagnosed SLOS patients reaches middle age, clinicians are starting to learn what the long-term trajectory looks like for those who make it through childhood. Most adults with SLOS continue to need some level of support. Intellectual disability, even when mild, often limits fully independent living. Behavioral challenges that were present in childhood frequently persist, although some individuals show improvement with consistent behavioral programs and medication management for irritability or anxiety.
Medical surveillance in adulthood tends to focus on growth and nutrition, since many adults with SLOS remain underweight; liver health, given the known risk of fibrosis; endocrine function, because cholesterol is the raw material for steroid hormones and deficiencies can affect puberty, bone density, and stress responses; and ongoing neuropsychiatric care. Adults with SLOS may also develop cataracts or other ophthalmologic issues at higher rates than the general population, likely related to oxidative damage in tissues with high cholesterol demand.
The honest picture is that SLOS remains a condition with no clear endpoint for medical management. For families, the practical takeaway is that survival past the first year, and particularly past the first few years without life-threatening organ malformations, is an encouraging sign. But “encouraging” does not mean the challenges resolve; they shift from acute, life-threatening crises to chronic management of development, behavior, nutrition, and organ function over a lifetime.